BioMarin Pharmaceuticals Inc (BMRN)
BioMarin Pharmaceuticals Inc. is a biotechnology company focused on developing and commercializing innovative therapies for rare genetic diseases. Founded in 1997, it specializes in treatments for conditions such as enzyme deficiencies, genetic disorders, and other underserved medical needs, offering its products primarily in the areas of neurology, inherited metabolic disorders, and hematology.
Company News
The AAV gene therapy market is projected to grow from $3.85 billion in 2025 to $78.56 billion by 2034, with a 40.1% CAGR. North America leads the market, driven by research investments, technological advancements, and increasing genetic disorder prevalence.
The Motley Fool podcast discusses potential acquisition targets, Tesla's decision to abandon its Dojo supercomputer project, and explores possible buyout candidates in various sectors including tech, pharmaceuticals, and apparel.
BioMarin reported strong Q2 earnings, beating estimates with $1.44 per share and $825.41 million in sales. The company discontinued its preclinical drug candidate BMN 390 but advanced BMN 333 with promising Phase 1 study results, targeting a potential 2030 launch.
The article identifies three stocks - Humana, Elevance Health, and BioMarin - that are currently oversold based on their Relative Strength Index (RSI) readings, suggesting potential for a rebound.
Mirum Pharmaceuticals (MIRM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.